According to FUNDER website data,
43 mutual funds hold NIS 48.89 million in Ofko Halat
Funds that hold significant holdings in the stock – for the full list of holdings
The following is a change in the holdings of mutual funds in Ofko’s share according to FUNDER-MVF data
Business developments:
BioReference Laboratories – A 170% increase in the volume of activity in the fourth quarter of 2020 compared to 2019. The number of PCR tests performed to detect the COVID-19 virus has increased by 24% compared to the third quarter of 2020
• During the fourth quarter, the company performed approximately 4.3 million PCR tests to detect the Covid-19 virus
• The company has the ability to provide over 100,000 tests a day
• performed approximately 220,000 serological tests for Covid-19 to measure the levels of specific SARS-CoV-2 antibodies; The company has a significant ability to provide additional testing
• Continues to provide innovative Covid-19 testing solutions for physicians, healthcare systems, government bodies, schools, employers, professional sports teams, cultural bodies and the general public through collaborations with Rite-Aid and CVS
• In January 2021, it reported agreements to conduct Covid-19 tests for players and officials, as well as teams and teams in the NBA Basketball League and the NHL Hockey League, along with support for leagues and other U.S. sporting events
BRL has launched a digital home diagnostics system
• Launched in January 2021 the Scarlet Health system, a digital platform that provides access to on-demand diagnostic services
• The system relies on the infrastructure of BRL, including the infrastructure of laboratories and specialists, nationwide, the subsidiary GeneDx has added repeated genetic tests
Launched a number of new genetic tests to diagnose different types of hereditary ataxias
• Offers a complete and cost-effective solution that covers most services for diagnosing hereditary ataxia in adults and children
Partner Pfizer’s application for approval of growth hormone Somatrogon was received and application for approval of the drug was submitted in Japan
• The FDA has accepted the application for marketing approval of Somatrogon for the treatment of children in the United States
• The PDUFA for the FDA decision is set for October 2021
• An application was submitted for approval of the drug in Japan and Pfizer meets the deadlines for submitting the application for approval of the marketing of Somatrogon in Europe in the first quarter of 2021
Marketing authorizations for the RAYALDEE drug have been received in 11 European countries
• Approvals have been received for the marketing of the RAYALDEE drug for the treatment of chronic kidney disease patients with grade 3 and 4 in Spain, Portugal, Italy and Switzerland, which are added to the countries of England, Germany, Sweden, Norway, Ireland, Denmark and the Netherlands.
• Commercial launch in these countries is expected to begin later this year
Financial results for the fourth quarter:
Pure profit In the fourth quarter of 2020, it totaled $ 32.3 million, or 5 cents per fully diluted share, compared to a net loss of $ 112.4 million or 18 cents per fully diluted share in the same period in 2019.
Revenue In the fourth quarter of 2020, they totaled $ 494.6 million compared to revenue of $ 224.3 million in the same period in 2019.
Diagnostics: Revenue from services in the fourth quarter of 2020 increased to $ 457.9 million compared to $ 177.9 million in the same period in 2019, and was mainly affected by the increase in the number of COVID-19 tests that was partially offset by a decrease in the number of clinical trials due to epidemics and reduced insurance indemnity. Genomics.
Total expenses Totaled $ 388.0 million in the fourth quarter of 2020 compared to $ 223.4 million in the fourth quarter of 2019, which reflected an operating profit of $ 69.9 million compared to an operating loss of $ 45.4 million in 2019. The increase in operating profit of approximately $ 115.3 million reflects an increase in the volume of tests as a result of performing the Covid-19 tests and a non-cash provision for impairment of $ 38.7 million included in the 2019 reports for goodwill and intangible assets attributed to the acquisition of Claros.
Pharmaceuticals: Revenues from products in the fourth quarter of 2020 totaled $ 30.8 million compared to $ 32.0 million in the fourth quarter of 2019, mainly due to a decline in RAYALDEE sales, which were adversely affected by the challenge of selling to patients in the face of the Covid-19 epidemic, which was offset by OPKO Chile sales . The number of prescriptions for RAYALDEE in the fourth quarter of 2020 decreased to about 15,000 compared to about 17,900 in the corresponding quarter in 2019.
Revenue from the sale of intellectual property totaled $ 5.9 million in the fourth quarter of 2020 compared to $ 14.4 million in the fourth quarter of 2019 reflecting a decrease in revenue recognition from payments received from Pfizer regarding Somatrogon. Total expenses totaled $ 45.7 million in the fourth quarter of 2020 compared to $ 103.2 million in the same period last year, mainly due to a non-cash provision for a loss of $ 53.1 million in the fourth quarter of 2019 due to goodwill and intangible assets related to acquisitions of CURNA and Transition Therapeutics. The operating loss amounted to $ 9.0 million in the fourth quarter of 2020 compared to $ 56.8 million in the fourth quarter of 2019.
Cash: Cash and cash equivalents amounted to $ 72.2 million, as of December 31, 2020. In addition, the company has a credit line from JP Morgan of $ 57.6 million and an unutilized credit line of $ 100 million that provides the company with access to additional capital, not diluting.